{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:25Z","timestamp":1740144025819,"version":"3.37.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004257","name":"Helse Vest","doi-asserted-by":"publisher","award":["912015"],"award-info":[{"award-number":["912015"]}],"id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40257-019-00434-w","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T06:40:23Z","timestamp":1554187223000},"page":"493-502","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effect of Biological Treatment on Fatigue in Psoriasis: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"20","author":[{"given":"Inger Marie","family":"Skoie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingvild","family":"Dalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roald","family":"Omdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"issue":"9997","key":"434_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983\u201394.","journal-title":"Lancet"},{"issue":"21","key":"434_CR2","first-page":"2095","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(21):2095\u20136.","journal-title":"N Engl J Med"},{"issue":"5","key":"434_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871\u2013881.e1\u201330.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"434_CR4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/jid.2009.319","volume":"130","author":"JT Elder","year":"2010","unstructured":"Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, et al. Molecular dissection of psoriasis: integrating genetics and biology. J Investig Dermatol. 2010;130(5):1213\u201326.","journal-title":"J Investig Dermatol"},{"issue":"5","key":"434_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496\u2013509.","journal-title":"N Engl J Med"},{"issue":"1","key":"434_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27\u201340.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"434_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"434_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/bjd.15375","volume":"177","author":"IM Skoie","year":"2017","unstructured":"Skoie IM, Dalen I, Ternowitz T, Jonsson G, Kvivik I, Norheim K, et al. Fatigue in psoriasis: a controlled study. Br J Dermatol. 2017;177(2):505\u201312.","journal-title":"Br J Dermatol"},{"issue":"6","key":"434_CR9","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/j.1365-2133.2007.07916.x","volume":"156","author":"EW Verhoeven","year":"2007","unstructured":"Verhoeven EW, Kraaimaat FW, van de Kerkhof PC, van Weel C, Duller P, van der Valk PG, et al. Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol. 2007;156(6):1346\u20139.","journal-title":"Br J Dermatol"},{"issue":"6","key":"434_CR10","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/00019052-199612000-00011","volume":"9","author":"LB Krupp","year":"1996","unstructured":"Krupp LB, Pollina DA. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol. 1996;9(6):456\u201360.","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"434_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.iac.2009.02.002","volume":"29","author":"R Dantzer","year":"2009","unstructured":"Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin N Am. 2009;29(2):247\u201364.","journal-title":"Immunol Allergy Clin N Am"},{"issue":"19","key":"434_CR12","doi-asserted-by":"publisher","first-page":"9117","DOI":"10.1073\/pnas.89.19.9117","volume":"89","author":"S Kent","year":"1992","unstructured":"Kent S, Bluthe RM, Dantzer R, Hardwick AJ, Kelley KW, Rothwell NJ, et al. Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. Proc Natl Acad Sci USA. 1992;89(19):9117\u201320.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"434_CR13","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.bbi.2011.04.001","volume":"25","author":"KV Reinertsen","year":"2011","unstructured":"Reinertsen KV, Grenaker Alnaes GI, Landmark-Hoyvik H, Loge JH, Wist E, Kristensen VN, et al. Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway. Brain Behav Immun. 2011;25(7):1376\u201383.","journal-title":"Brain Behav Immun"},{"issue":"3","key":"434_CR14","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.10.008","volume":"24","author":"K Becker","year":"2015","unstructured":"Becker K, Kohen R, Lee R, Tanzi P, Zierath D, Cain K, et al. Poststroke fatigue: hints to a biological mechanism. J Stroke Cerebrovasc Dis. 2015;24(3):618\u201321.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"Suppl. 10","key":"434_CR15","first-page":"2017","volume":"69","author":"KAA Norheim","year":"2017","unstructured":"Norheim KAA, Imgenberg-Kreuz J, Brun JG, Jonsson R, Ng WF, Theander E, Mandl T, Sivils KL, R\u00f6nnblom L, Nordmark G, Omdal R. Genetic determinants of fatigue in primary Sj\u00f6gren\u2019s syndrome: a genome wide association study. 2017 ACR\/ARHP Annual Meeting, San Diego, CA. Arthritis Rheumatol. 2017;69(Suppl. 10):2017.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"434_CR16","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/rheumatology\/kew008","volume":"55","author":"K Braekke Norheim","year":"2016","unstructured":"Braekke Norheim K, Imgenberg-Kreuz J, Jonsdottir K, Janssen EA, Syvanen AC, Sandling JK, et al. Epigenome-wide DNA methylation patterns associated with fatigue in primary Sjogren\u2019s syndrome. Rheumatology (Oxford). 2016;55(6):1074\u201382.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 11","key":"434_CR17","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1002\/acr.20579","volume":"63","author":"S Hewlett","year":"2011","unstructured":"Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res (Hoboken). 2011;63(Suppl. 11):S263\u201386.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"434_CR18","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121\u20133.","journal-title":"Arch Neurol"},{"issue":"7","key":"434_CR19","first-page":"1261","volume":"32","author":"F Wolfe","year":"2005","unstructured":"Wolfe F, Michaud K, Pincus T. Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. J Rheumatol. 2005;32(7):1261\u20136.","journal-title":"J Rheumatol"},{"issue":"2","key":"434_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13(2):63\u201374.","journal-title":"J Pain Symptom Manag"},{"issue":"3","key":"434_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0022-3999(94)00125-O","volume":"39","author":"EM Smets","year":"1995","unstructured":"Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315\u201325.","journal-title":"J Psychosom Res"},{"issue":"4","key":"434_CR22","first-page":"639","volume":"22","author":"BL Belza","year":"1995","unstructured":"Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol. 1995;22(4):639\u201343.","journal-title":"J Rheumatol"},{"issue":"6","key":"434_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care"},{"key":"434_CR24","first-page":"CD008334","volume":"6","author":"C Almeida","year":"2016","unstructured":"Almeida C, Choy EH, Hewlett S, Kirwan JR, Cramp F, Chalder T, et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev. 2016;6:CD008334.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"434_CR25","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/bjd.13647","volume":"172","author":"IM Skoie","year":"2015","unstructured":"Skoie IM, Ternowitz T, Jonsson G, Norheim K, Omdal R. Fatigue in psoriasis: a phenomenon to be explored. Br J Dermatol. 2015;172(5):1196\u2013203.","journal-title":"Br J Dermatol"},{"issue":"4","key":"434_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"1","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;1(4):1.","journal-title":"Syst Rev"},{"issue":"10","key":"434_CR27","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1111\/jdv.13702","volume":"30","author":"F Valenzuela","year":"2016","unstructured":"Valenzuela F, Paul C, Mallbris L, Tan H, Papacharalambous J, Valdez H, et al. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a phase 3 study. J Eur Acad Dermatol Venereol. 2016;30(10):1753\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"434_CR28","volume-title":"Cochrane handbook for systematic reviews of interventions. S.l.","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Green S, Cochrane C. Cochrane handbook for systematic reviews of interventions. S.l. London: The Cochrane Collaboration; 2011."},{"issue":"1","key":"434_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1365-2133.2009.09491.x","volume":"162","author":"M Lebwohl","year":"2010","unstructured":"Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol. 2010;162(1):137\u201346.","journal-title":"Br J Dermatol"},{"issue":"3","key":"434_CR30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"434_CR31","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1365-2133.2008.08727.x","volume":"159","author":"SR Feldman","year":"2008","unstructured":"Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159(3):704\u201310.","journal-title":"Br J Dermatol"},{"key":"434_CR32","first-page":"4","volume":"44","author":"MJ Bradburn","year":"1999","unstructured":"Bradburn MJ, Deeks JJ, Altman DG. Metan: an alternative meta-analysis command. Stata Techn Bull. 1999;44:4\u201315.","journal-title":"Stata Techn Bull"},{"issue":"6","key":"434_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/09546630701646172","volume":"18","author":"DA Revicki","year":"2007","unstructured":"Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatol Treat. 2007;18(6):341\u201350.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"434_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/09546630601121060","volume":"18","author":"R Shikiar","year":"2007","unstructured":"Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatol Treat. 2007;18(1):25\u201331.","journal-title":"J Dermatol Treat"},{"issue":"9504","key":"434_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","volume":"367","author":"S Tyring","year":"2006","unstructured":"Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29\u201335.","journal-title":"Lancet"},{"key":"434_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/9780470743386","volume-title":"Introduction to meta-analysis","author":"M Borenstein","year":"2009","unstructured":"Borenstein M. Introduction to meta-analysis. Chichester: Wiley; 2009."},{"issue":"6","key":"434_CR37","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/j.1365-2133.2006.07237.x","volume":"154","author":"K Reich","year":"2006","unstructured":"Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006;154(6):1161\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"434_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1536867X0800800102","volume":"8","author":"R Harris","year":"2008","unstructured":"Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J. Metan: fixed- and random-effects meta-analysis. Stata J. 2008;8(1):3\u201328.","journal-title":"Stata J"},{"issue":"3","key":"434_CR39","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","volume":"4","author":"GM Sullivan","year":"2012","unstructured":"Sullivan GM, Feinn R. Using effect size: or why the p value is not enough. J Grad Med Educ. 2012;4(3):279\u201382.","journal-title":"J Grad Med Educ"},{"issue":"3","key":"434_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000237871","volume":"219","author":"K Reich","year":"2009","unstructured":"Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, et al. Once-weekly administration of etanercept 50\u00a0mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology. 2009;219(3):239\u201349.","journal-title":"Dermatology"},{"issue":"6","key":"434_CR41","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/j.1365-2133.2005.06948.x","volume":"153","author":"GG Krueger","year":"2005","unstructured":"Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153(6):1192\u20139.","journal-title":"Br J Dermatol"},{"issue":"9","key":"434_CR42","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1346-8138.2012.01521.x","volume":"39","author":"H Nakagawa","year":"2012","unstructured":"Nakagawa H, Schenkel B, Kato M, Kato T, Igarashi A. Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2\/3 trial. J Dermatol. 2012;39(9):761\u20139.","journal-title":"J Dermatol"},{"issue":"3","key":"434_CR43","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.346-8138.2011.01347.x","volume":"39","author":"A Igarashi","year":"2012","unstructured":"Igarashi A, Kato T, Kato M, Song M, Nakagawa H. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial. J Dermatol. 2012;39(3):242\u201352. \n                    https:\/\/doi.org\/10.1111\/j.346-8138.2011.01347.x\n                    \n                  \n                           (Epub 2011 Sep 29).","journal-title":"J Dermatol"},{"issue":"1","key":"434_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","volume":"81","author":"H Nakagawa","year":"2016","unstructured":"Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44\u201352.","journal-title":"J Dermatol Sci"},{"issue":"13","key":"434_CR45","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","volume":"366","author":"KA Papp","year":"2012","unstructured":"Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"434_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2310\/7750.2010.10009","volume":"15","author":"S Jankovic","year":"2011","unstructured":"Jankovic S, Raznatovic M, Marinkovic J, Jankovic J, Kocev N, Tomic-Spiric V, et al. Health-related quality of life in patients with psoriasis. J Cutan Med Surg. 2011;15(1):29\u201336.","journal-title":"J Cutan Med Surg"},{"issue":"9","key":"434_CR47","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/rheumatology\/kep141","volume":"48","author":"JM Meijer","year":"2009","unstructured":"Meijer JM, Meiners PM, Huddleston Slater JJ, Spijkervet FK, Kallenberg CG, Vissink A, et al. Health-related quality of life, employment and disability in patients with Sjogren\u2019s syndrome. Rheumatology (Oxford). 2009;48(9):1077\u201382.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"434_CR48","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/art.21450","volume":"53","author":"S Hewlett","year":"2005","unstructured":"Hewlett S, Cockshott Z, Byron M, Kitchen K, Tipler S, Pope D, et al. Patients\u2019 perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheumatol. 2005;53(5):697\u2013702.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"434_CR49","doi-asserted-by":"publisher","first-page":"e30123","DOI":"10.1371\/journal.pone.0030123","volume":"7","author":"KB Norheim","year":"2012","unstructured":"Norheim KB, Harboe E, Goransson LG, Omdal R. Interleukin-1 inhibition and fatigue in primary Sjogren\u2019s syndrome: a double blind, randomised clinical trial. PLoS One. 2012;7(1):e30123.","journal-title":"PLoS One"},{"issue":"1","key":"434_CR50","doi-asserted-by":"publisher","first-page":"31.e1\u201315","DOI":"10.1016\/j.jaad.2006.07.017","volume":"56","author":"A Menter","year":"2007","unstructured":"Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1\u201315.","journal-title":"J Am Acad Dermatol"},{"issue":"9993","key":"434_CR51","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","volume":"386","author":"H Bachelez","year":"2015","unstructured":"Bachelez H, Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552\u201361.","journal-title":"Lancet"},{"issue":"9494","key":"434_CR52","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367\u201374.","journal-title":"Lancet"},{"issue":"4","key":"434_CR53","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","volume":"55","author":"KB Gordon","year":"2006","unstructured":"Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598\u2013606.","journal-title":"J Am Acad Dermatol"},{"key":"434_CR54","unstructured":"Reich KG, Foley P, Song M, Wasfi Y, Li S, Shen YK, Han C, Armstrong A. General health-related quality of life among plaque psoriasis patients treated with guselkumab or adalimumab: results from a phase 3 randomized clinical trial. In: 26th EADV Congress, 13\u201317 Sep 2017, Geneva."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00434-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-019-00434-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00434-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T23:25:12Z","timestamp":1585697112000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-019-00434-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1007\/s40257-019-00434-w","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"type":"print","value":"1175-0561"},{"type":"electronic","value":"1179-1888"}],"subject":[],"published":{"date-parts":[[2019,4,2]]},"assertion":[{"value":"2 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Inger Marie Skoie received support as a doctoral research fellow from the Western Norway Regional Health Authority (\u201cHelse Vest\u201d), Grant No. 912015.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Inger Marie Skoie has received honoraria for participation in advisory boards and\/or as a speaker for AbbVie, Janssen, Eli Lilly, Leo Pharma, and Pfizer pharmaceutical companies. Ingvild Dalen and Roald Omdal have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}